Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FERMATA: Prolgolimab in Advanced Cervical Cancer
NCT03912415Phase 3Unknown
- Sponsor
- BIOCAD
- Start
- Oct 2019
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of prolgolimab in Cervical Cancer (CC), sponsored by BIOCAD. Status: unknown.
02
Drugs
prolgolimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03912415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912415.